JUL 20, 2016 08:00 AM PDT

Using multiplexed IHC to effectively navigate the hidden clues of the immunological microenvironment

Speakers
  • Field Applications Scientist, PerkinElmer
    Biography
      Dr. Stack completed his undergraduate education at Stony Brook University in Stony Brook, New York prior to his Ph.D. studies at Boston College in Chestnut Hill, Massachusetts. He carried out postdoctoral research at Boston University, where he began to develop his interests in human translational research. Dr. Stack has carried out many oncology studies examining disease mechanisms in multiple cancer types while at the Dana-Farber Cancer Institute, where he was the associate director of the Dana-Farber/Brigham and Women's Center for Molecular Oncologic Pathology, and an instructor in the Pathology Department of Brigham and Women's and the Harvard Medical School. Dr. Stack was also a member of the Dana-Farber/Harvard Cancer Center in both the gastrointestinal malignancies and prostate cancer research programs. Dr. Stack is currently a pathology scientist at PerkinElmer, where he is interested in developing cancer immunology-focused, tissue-based assays, which can provide deeper insights into cancer-host interactions and assist in clinical management of cancer.

    Abstract:
    DATE: July 20th
    TIME: 8AM PT, 11AM ET, 5PM CEST


    Therapies like ipilimumab and nivolumab  have shown the potential for approaches that direct the patient’s own immune system against tumors.  Further advances will require a detailed understanding of the tumor microenvironment and characterization of the location and status of immune cells and their interaction with tumor cells.  This will require methods that provide phenotyping of immune and cancer cells combined with the cytoarchitectonics of the tumor. To achieve this, a practical method for simultaneous immunohistochemistry of up to 8 biomarkers in a single tissue section using standard unlabeled primary antibodies will be described. In addition, approaches for multiplexed imaging, single cell quantitative analysis, automated phenotyping and bioinformatics that enable new insights into cancer biology and immunology will be presented. These will then be leveraged in analyses of multiple cancer types, where it is established that the host-tumor interaction is complex and difficult to characterize with standard immunohistochemistry or flow cytometry. But by leveraging multiplexed IHC in situ, we will demonstrate the unique spatial relationships of immune phenotypes in and around both epithelial and non-epithelial tumor types, and show how this data has the potential to form the basis of assays that can guide therapy and monitor response. Further data regarding functional assessment of regulatory immunologic co-factor expression will be discussed.
     

    Show Resources
    You May Also Like
    NOV 15, 2018 10:00 AM PST
    C.E. CREDITS
    NOV 15, 2018 10:00 AM PST
    DATE:  November 15, 2018TIME:  10:00am PT, 1:00pm ET Multiplex fluorescence immunohistochemistry offers a window into the biology of human disease, enabling the ana...
    NOV 07, 2018 08:00 PM PST
    C.E. CREDITS
    NOV 07, 2018 08:00 PM PST
    DATE: November 7, 2018TIME: 8:00PM PSTExosomes have been shown to have significant roles in cancer including disease progression acting in the tumor micro-environment, metasta...
    NOV 07, 2018 07:00 AM PST
    C.E. CREDITS
    NOV 07, 2018 07:00 AM PST
    DATE: November 7, 2018TIME: 7:00AM PDTExosomes have been shown to have significant roles in cancer including disease progression acting in the tumor micro-environment, metastasis a...
    MAR 26, 2019 02:00 PM PDT
    C.E. CREDITS
    MAR 26, 2019 02:00 PM PDT
    DATE:  March 26, 2019TIME:  2:00pm PDT, 5:00pm EDT  Prostate cancer is the second most common form of cancer in males, affecting one in eight men by the time t...
    MAY 21, 2019 07:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 21, 2019 07:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: May 21, 2019TIMEL 7:00am PT, 10:00am ET Human T cells are central effectors of immunity and cancer immunotherapy. CRISPR-based functional studies in T cells could prioriti...
    DEC 06, 2018 09:00 AM PST
    C.E. CREDITS
    DEC 06, 2018 09:00 AM PST
    DATE:   December 6, 2018TIME:    9:00am PST, 12:00pm EST Induced pluripotent stem cells (iPSC) intended for translational applications need to be of...
    Loading Comments...
    Show Resources